Premium
Antiangiogenic and hypolipidemic activity of coenzyme Q 10 supplementation to breast cancer patients undergoing Tamoxifen therapy
Author(s) -
Sachdanandam Panchanatham
Publication year - 2008
Publication title -
biofactors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.204
H-Index - 94
eISSN - 1872-8081
pISSN - 0951-6433
DOI - 10.1002/biof.5520320118
Subject(s) - tamoxifen , coenzyme q10 , medicine , breast cancer , angiogenesis , hypertriglyceridemia , metastasis , oncology , cancer , disease , estrogen , endocrinology , cancer research , cholesterol , triglyceride
Tamoxifen, a non‐steroidal anti‐estrogen is now widely used and has led to an increase in both disease‐free and overall survival of women after primary surgery. Tamoxifen therapy is found to cause hypertriglyceridemia by reducing activity of lipolytic enzymes on triglycerides, and thereby increasing the risk of cardiovascular disease. Angiogenesis promotes local tumour progression and invasion and enables tumour cell dissemination and metastasis formation. Our study has found that co‐administration of Coenzyme Q 10 (100 mg) along with tamoxifen (10 mg, twice a day) to breast cancer patients reduced the level of angiogenesis markers and lipid levels.